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1. Introduction
Dementia is defined as a clinical syndrome characterized by progressive deterioration in
multiple cognitive domains that are severe enough to interfere with daily functioning, in‐
cluding social and professional functioning. Alzheimer disease (AD) is the most common
form of dementia often diagnosed in people over 65 years old, even though the early-onset
AD can occur much earlier since 40 years of age. AD is a multifactorial disorder in which the
causes and the progression are still not well-understood. Aging is the most common non-
modifiable cause of dementia in the elderly, but it accounts only for approximately half of
all cause. Research identified other potential causes among the interaction between modifia‐
ble environmental factors, such as vascular disease and genetic susceptibility. The recent ge‐
netic discoveries have shown that mutation of the β-amyloid precursor protein on
chromosome 21, and the mutations of presenilin 1 and presenilin 2 on chromosome 14 and
1, were associated with increased susceptibility of AD. Finally, the presence of the ε4 allele
of Apolipoprotein E (APOE) is considered as a risk factor for late-onset of AD. The Diagnos‐
tic and Statistical Manual on Mental Disorders, fourth edition text revised (DSM-IV-TR), de‐
fines dementia as an acquired disease characterized by decline in memory and at least one
other cognitive function such as attention, visuo-spatial skills, language, or executive func‐
tions. Beside the cognition, the disease affects the emotional abilities and interferes signifi‐
cantly with work and daily-life activities. Dementia can be defined as either possible, or
probable based on the recent published diagnostic criteria [1]. Since 1980s, numerous com‐
munity-based prospective studies of aging and health have been implemented in the world;
many of which have focused on dementia and its main subtypes of AD and vascular demen‐
tia (VaD). In this Chapter, we review the literature of clinical and epidemiological research
in the dementias by focusing on most recent studies.
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AD is an age-related phenomenon and is the most common cause of dementia, but increas‐
ing evidence from population-based neuropathological and neuroimaging studies shows
that mixed brain pathology (neurodegenerative and vascular) account for a large number of
dementia cases, especially in very old people [2]. According to the World Alzheimer Report,
there were 35.6 million people living with dementia worldwide in 2010, a number that will
increase to 65.7 million by 2030 and 115.4 million by 2050 unless effective means of reducing
disease incidence are introduced. The total estimated worldwide costs of dementia were US
$604 billion in 2010, including the costs of informal care, direct costs of social care, and the
direct costs of medical care [3]. Increasing age is a well-established risk factor for dementia
and AD. Both prevalence and incidence of AD increases exponentially with advancing age,
and 70% of all dementia cases occur in people aged 75+ years [4]. Notwithstanding, despite
the incidence rate of AD increases almost exponentially until 85 years of age, it remains un‐
certain whether the incidence continues to increase even at more advances ages or reaches a
plateau [5]. In Europe, the age-adjusted prevalence is 6.4% for dementia in general, and 4.4%
for AD among people 65 years and older [6]. In the US, has been estimated that the 9.7% of
people aged 70+ years has AD [7]. More than 25 million people in the world are affected by
dementia; most of them suffer from AD, with about 5 million new cases every year [8, 9].
The estimated global annual incidence is around 7.5 per 1000 people [8]. The incident rate
increases from approximately one per 1000 person-year in people aged 60-64 to more than
70 per 1000 person-year in 90+ years-old. In Europe, the pooled incidence rate of AD in peo‐
ple aged 65 years and older was 19.4 per 1000 person-year. The incidence rates of AD across
different regions are quite similar in the younger-old, but greater variations have been seen
among the older ages, but this is probably because of differences in methodology such as
study designs and case ascertainment [5]. In conclusion, the worldwide population aging
explains the epidemic proportions for dementia making the disease an important issue for
the public health.
2. Pathogenesis and mechanisms of AD
Alzheimer’s disease has not a single cause but is the results of the interaction of multiple
mechanisms that can be grouped into aging, genetic influence, vascular pathology, inflam‐
mation and environmental influence such as toxic exposure. However, currently, the precise
pathogenesis of AD is not known. One of the most important pathologic features character‐
ising AD is the brain atrophy which results by loss of neurons, synapses and dendritic arbo‐
rization in the cerebral cortex and subcortical regions. Cerebral atrophy is associated with
the presence of neurofibrillary tangles and amyloid plaques, two hallmarks over-expressed
in AD brain [10]. Neurofibrillary tangles are insoluble aggregates of hyperphoshorylated
microtubule-associated tau protein that become accumulate inside the cells themselves.
Changes in tau protein lead to the disintegration of the brain microtubules, the main neu‐
ron’s transport system [11]. Amyloid plaques are dense and insoluble extracellular deposits
of β-amyloid peptide (Aβ). Aβ derived from APP protheolisis. This transmembrane protein
is divided into smaller fragments by three different enzymes: α, β, and γ–secretases. The
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cleavage of APP by β, and γ–secretases creates Aβ42 peptide, while the cleavage by α-secre‐
tase produce Aβ40. Aβ42 peptide aggregates more readily than Aβ 40, and the ratio of these
two isoforms influence the formation of the senile plaques [12]. Genetic studies [13] have
identified mutations in APP and presenilin 1 and 2 (components of the γ-secretase) that
cause rare, dominantly inherited familial AD. These findings strongly supported the amy‐
loid hypothesis [14], which posits that β-amyloid peptides play a pivotal role in AD patho‐
genesis. The amyloid cascade hypothesis suggests that deposition of Aβ triggers neuronal
dysfunction and death in the brain. In the original hypothesis, this neuronal dysfunction
and death was thought to be a toxic effect of the total amyloid load.
As knowledge of pathological changes in Alzheimer’s disease increased, research identified
Aβ oligomers as the principle players of the toxic effect [10]. Changes in tau phosphoryla‐
tion status and consequent neurofibrillary tangles formation are also triggered by toxic con‐
centrations of Aβ [14]. All the factors mentioned above (aging, genes, inflammation, and
vascular pathology) can increase the production of Aβ. Despite genetic and cell biological
evidence support the amyloid hypothesis [15], which is also the target of the new immuno‐
therapies for AD, it is becoming clear that AD etiology is complex and that Aβ alone is un‐
able to account for all the aspects of the disease. Others amyloid- independent hypothesis
have been proposed [16]. The inflammatory hypothesis is based on the presence of activated
microglia in AD brain. These cells, which have been shown to cluster around senile plaques,
produce massive amounts of oxygen radicals and inflammatory mediators that are toxic to
brain cells ultimately destroying them [17]. There is general agreement that the overproduc‐
tion of free radicals generated from oxidative stress has a major role in neurodegeneration
[18] and, as a reactive process, it may be involved in cell cycle regulation contributing to cell
death [19]. In brain, a variety of stressants can induce oxidative stress as cerebral hypoperfu‐
sion, inflammation, aging, hypoxia, cigarette smoking, excess alcohol, or cardiovascular dis‐
ease. There is also a vascular hypothesis that suggests that cerebral hypoperfusion in the
presence of vascular risk factors can further lower cerebral blood flow to a critical level that
threatens neuronal survival [20, 21]. Many other mechanisms have been suggested and can
be involved in AD neurodegeneration, anyhow none hypothesis alone can explain the
pathogenesis of AD [22].
3. Risk factors
The aetiology of dementia and AD has been extensively studied trying to find efficacious
prevention and treatment strategies. As said, dementia is a multifactorial disorder caused by
complex interaction between environmental and genetic factors. It has been estimated that
1-5% of AD cases are due to genetic mutations, while the most part are ascribable to modifi‐
able environmental factors and their interaction with genetic susceptibility [10]. Age is the
most powerful determinant of dementia, suggesting that aging-related biological process
may be involved in the pathogenesis of AD [23]. In actuality, the association between age
and AD is mediated by the cumulative effect of other risk and protective factors over the
lifespan. The major risk and protective factors for AD can be summarized basing on the dif‐
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ferent etiological hypotheses including genetic susceptibility hypothesis, vascular pathway
hypothesis, psychosocial hypothesis, nutrition and dietary hypothesis, and others (e.g., toxic
or inflammatory factors). While the role of genetic, vascular and psychosocial factors in the
AD onset is supported by strong to moderate epidemiological, neuroimaging and neuropa‐
thological researches, the evidences for the other factors are controversial and insufficient
[5]. Following age, the presence of Apolipoprotein E ε4 allele (APOE ε4) is the most estab‐
lished genetic risk factor for developing late-onset AD. There are three forms of APOE al‐
leles, ε2, ε3, and ε4, APOE ε4 increased the risk of AD by three times in heterozygote and
more in homozygote, while ε2 decreases the risk [24, 25]. APOE allele ε4 is a susceptibility
gene, being neither necessary nor sufficient for the development of AD.
In the last decade many others AD susceptibility genes have been identified, highlighting
the importance of a genetic susceptibility for AD development [26]. Over the last decade,
great attention has been paid to figure out which AD-related factors may be modified to de‐
crease the risk of AD. Two groups of modifiable factors for late-life dementias have been
identified as “vascular risk factors” that have been strongly associated with an increased
risk of dementia; and the “psychosocial factors” that may contribute to the delay of demen‐
tia onset. Strong epidemiological evidences suggested that cardiovascular risk factors and
vascular disease are associated with an increased risk of symptomatic AD [27].Thus, studies
revealed age-dependents associations with AD for several aging-related conditions. The
most important cardiovascular risk factors for subsequent AD include cigarette smoking [28,
29], heavy alcohol consumption [30], midlife high blood pressure [31], atrial fibrillation and
heart failure [32], spontaneous cerebral emboli [33], midlife obesity or central adiposity as
well as low BMI in late-life [34-36], midlife high cholesterol levels [37], diabetes mellitus and
impaired glucose regulation [38-40], neuroinflammation [41, 42], and elevated plasma and
total homocysteine levels [43].
Other risk factors for AD may include traumatic brain injury, late-life metabolic syndrome
and depression, but their role is not clear and studies with long-term follow-up need to sup‐
port the risk factors hypothesis [44, 45]. About psychological factors epidemiological re‐
search has been accumulating that some psychosocial factors and healthy lifestyle such as
the social network and social engagement, weekly-to-daily physical activity, higher educa‐
tional and socio-economic status and mentally stimulating activity, may postpone the onset
of dementia by enhancing cognitive reserve [3, 46-48]. In addition, several studies reported a
decreased risk of AD and dementia associated with a diet rich in both high polyunsaturated
and fish-related fatty acids, such as the Mediterranean diet [49], and elevated levels of vita‐
min B12 and folate (50). Finally, controversy exists about the role of hormone replacement
therapy with estrogens and progestin and subsequent development of AD. Several studies
suggest that normal age-related depletion of estrogens in women and testosterone in men
may represent potential risk factors for AD’s onset [51], suggesting hormone replacement
therapy (HRT) as method to reduce risk of late-life AD in postmenopausal women. Never‐
theless, the therapeutic effects of HRT is not supported by the Cochrane’s review, which
found that HRT or estrogens for improving or maintaining cognition was not indicated for
women with AD [52].
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4. Clinical features
A peculiar feature of AD is the progressive and multi-focal cognitive deterioration charac‐
terized by the insidious onset, the absence of focal neurological signs, and memory disor‐
ders. It develops slowly and gets worse overtime. Progressing, the disease damages the
most areas of the brain, and this is manifested through the gradually deterioration of memo‐
ry, attention, executive functions, language, praxia, movement and personality. AD should
be suspected when any individual, without alterations of awareness, refers generalized epi‐
sodic memory disturbances with insidious onset that escalate up to interfere with daily liv‐
ing, social and/or occupational activities. In an attempt to help clinicians in recognizing the
severity of disease, the Mayo Clinic group proposes three main stages in the natural history
of AD, each characterized by distinctive symptoms and duration. The classification has been
made based on clinical experience and generalization. It is not intended to be in an inflexible
and taxonomic way, but it is important to realize that AD is the neurodegenerative process
of the single person, and thus the duration and the type of symptoms may change from one
patients to another. Considering that, it is helpful divide the AD progression into following
stages: 1) “Early stage” characterized mainly by memory disorders; 2) “Moderate stage”
where appears progressive cortical dysfunction (apraxia, aphasia, visuo-spatial disturbance)
and disorders of instrumental functions; 3) “Advanced stage” with disorders of the ”Con‐
trol” functions and rise of neuropsychiatric disorders.
People may manifest mild symptoms long time before the clinical diagnosis of AD and often
they are underestimated and mistakenly ascribe to either aging or stress. The early detection
of symptoms is difficult because of the absence of a definite time of disease onset, so in the
clinical practice patients with dementia are often first diagnosed when the disease is ad‐
vanced to the early stage with the clear manifestation of cognitive and behavioural disorders
[53]. The prodromal stage of the disease is known as “Mild cognitive impairment” (MCI) in‐
dicating those people likely to be in the earliest stage of dementia, but with so mild symp‐
toms that cannot be formulate a formal diagnosis of dementia. Patients with MCI typically
present forgetfulness due to the episodic memory impairment that leads to difficulties of re‐
call and learning new information, but they do not have a clear deficit in daily functioning,
being able to live independently with a minimal help [54]. Not all the subjects with MCI de‐
velop dementia, but all subjects affected by AD had first presented this mild stage. It is ac‐
cepted that AD pathogenesis starts decades before clinical manifestation and that subjects
decline slowly in cognition for years before meeting the diagnostic criteria for dementia [55,
56]. Longitudinal studies have shown that people with MCI have a high probability to de‐
velop dementia within 1-3 years after diagnosis [54]. When the progression of memory im‐
pairment and the decline in other cognitive domains (executive function, visuo-spatial,
language, behaviour or personality) significantly interfere with the ability to function at
work or at usual activities, the criteria for diagnosis of dementia are met [1]. The AD’s “Mild
stage” can last from 2 to 4 years. The typical scenario includes memory impairment for re‐
cent events with relative sparing for remote events (autobiographical memory), prospective
memory disorders (remembering to perform a planned action or intention at the appropri‐
ate moment), difficulty with problem solving, complex task and sound judgment, difficulty
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to organize and express thoughts, deficit in the ability to plan and execute actions in a cor‐
rect sequence (executive function and apraxia), slowing in the ability to switch from one ac‐
tivity to another [54]. In addition, patients in the mild stage may start to present sporadic
language disorders mainly characterized by decreased vocabulary and word fluency with a
subsequent impoverishment of the speaking and writing [57].
Neurocognitive studies show that the episodic memory impairment is due to a deficit of
storage newly acquired information in long-term memory [58] reflecting an early impair‐
ment of the “central executive” component of the working memory with relative sparing of
the “slave systems”. In this stage it is also likely that personality changes appear and the
most prominent is apathy with symptoms of diminished interests and concerns and may be
associated with depression. Social withdrawal, fluctuating mood, irritability or anxiety are
less frequent. In some cases the non-cognitive symptoms may be more prominent than the
cognitive impairment complicating the care of patients with AD. Despite that, they are not
present in all patients and are not constantly progressive as the cognitive deficits. Decreased
attention and motivation to complete task as well as dresses inappropriately are also com‐
mon. Towards the end of the mild stage, patients may start to be confused especially in un‐
familiar place, reflecting the onset of orientation defects. The “Moderate stage” of AD is the
longest stage lasting from 2 to 10 years. The cognitive and behavioural symptoms increase
in the severity, people get more confused and forgetful and the progressive deterioration in‐
terfere with individual independence, with person being unable to perform most common
daily living activities and self-care. On cognition, the middle stage is characterized by a pro‐
gressive cortical dysfunction with prominent language, praxis, visuo-spatial, executive func‐
tion and abstract reasoning disorders. Progressive deterioration of oral and written
communication includes anomias of aphasic lexico-semantic origin that progress into a flu‐
ent aphasia, speech planning defects and “empty speech” because of inability to recall vo‐
cabulary which leads to semantic paraphasias, progressive loss of reading and writing.
Ideational and ideo-motor apraxia is responsible for difficulties in number processing and
calculation. Memory impairment worsen may involve also the autobiographical memory.
Disturbance of visuo-perceptual contour processing and spatial processing evolve leading
to deficit in recognizing familiar faces (prosopagnosia) and person, geographical and envi‐
ronmental disorientation, difficulty in coping figure, and visual imagery deficits. Patients
become less able to succeed the more demanding tasks of daily living, such as manage fi‐
nances  and driving.  The personality  and behavioural  changes  worsen.  Psychotic  behav‐
iour, paranoia, delusions, auditory or visual hallucinations are not unusual in this stage.
Common manifestations are labile affect,  irritability,  wandering,  aggression or resistance
to  caregiver.  Sleep disorders  including disruption in  the  sleep/wake cycle,  sundowning,
and  urinary  incontinence  can  develop.  Patients  lose  awareness  of  their  disease  process
and limitation (anosognosia). In the AD’s “Severe stage” (1-3+ years), patients generally
lose the ability to communicate coherently, and experience a great decline in physical abil‐
ities  becoming mostly dependent on caregiver for  feeding and hygiene.  Language is  re‐
duced to single simple phrases or words. Despite the severity of communication problem,
people can understand and return emotional signal. On the behavioural level, aggressive‐
ness can be still present, but severe apathy and exhaustion are common symptoms. Neu‐
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rological  disorders  (tonic  grasping,  echolalia,  oral  grasping,  Kluver-Bucy  syndrome and
bilateral apraxia), and motor abnormalities can develop. Muscle mass and mobility deteri‐
orate  until  the  patient  is  completely  bedridden  and  not  self-sufficient.  People  with  AD
typically die from medical complication as bronchitis, pneumonia, or pressure ulcers, and
not because of disease itself [59, 60].
5. Alzheimer’s disease diagnosis
The 1984 criteria made by the National Institute of Neurologic, Communicative Disorders
and Stroke/Alzheimer’s disease and Related Disorders Association (NINCDS-ADRDA)
work group [61] were based on doctor’s clinical judgment about the cause of patient’s symp‐
toms, taking into account reports from the patient and family members, and results of cogni‐
tive tests and general neurological assessment. These criteria have been quite successful and
they have been widely used in clinical trials and clinical research, showing a sensitivity of
81% and specificity of 70% [62]. However, the increasing knowledge of the clinical manifes‐
tations and biology of AD determined the need of criteria revision. After 27 years, in 2011
the National Institute on Aging (NIA) and the Alzheimer’s Association recommended new
diagnostic criteria and guidelines for Alzheimer’s disease [1,55,56]. The notable changes of
the 2011 criteria are mainly due to the concept that the pathophysiological process of AD
begins years, if not decades, before the diagnosis of clinical dementia, and to the incorpora‐
tion of biomarkers that can indicate the presence or absence of AD pathology. The new crite‐
ria propose three different stages of Alzheimer’s disease: preclinical AD, MCI due to AD,
dementia due to AD. The preclinical stage occurs before symptoms development and indi‐
cates cognitive intact subjects with positive biomarkers of AD-related brain changes [55]. Ta‐
ble 1 shows diagnostic criteria of the different stages of preclinical AD phase. The
investigation of the presence of this stage is strictly for research purposes only and usually
used for individuals with high genetic risk of AD. Individuals with MCI have mild but
measurable changes in cognition that are noticeable to the person affected and to family and
friends but that do not affect the individual’s ability to carry out everyday activities. Not all
the subjects with MCI develop dementia, it is estimated that the rate of progression can be
10% per year. It is unclear why some individual progress into dementia and some others
not, however it is believed that MCI can be an early stage of dementia. In the new criteria
(Table 2) the use of biomarkers is suggested in order to investigate whether subjects have
brain changes that put them at higher risk of developing AD. If biomarkers of AD-pathology
result positive the diagnosis is MCI due to AD [56].
The new criteria proposed to classify people with AD dementia in the following groups af‐
ter meet general criteria for dementia [1]: 1) Probable AD dementia, 2) Possible AD demen‐
tia, and 3) Probable or Possible AD dementia with evidence of the AD pathophysiological
process. Table 3 shows the revised criteria for AD. The first two have been planned to use in
a clinical setting and are very much similar to the previous NINCS-ADRDA criteria of possi‐
ble and probable AD. The third group has been suggested only for research field.
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Aβ (PET or CSF) Markers of neuronal
injury
(tau CZ-F, PET-FDG, MRI)
Evidence of subtle
cognitive change
Asymptomatic cerebral amyloidosis Positive Negative Negative
Asymptomatic cerebral amyloidosis +
neurodegeneration
Positive Positive Negative
Amyloidosis+ neuronal injury+ subtle
cognitive/ behavioral decline
Positive Positive Positive
(Sperling RA et al. 2011) [55]
Table 1. Pre-clinical Alzheimer´s Disease stages: National Institute on Aging (NIA) and the Alzheimer’s Association
diagnostic criteria 2011.
MCI- core clinical criteria
• Cognitive concern reflecting a change in cognition reported by patient or informant or clinician (i.e., historical or
observed evidence of decline over time)
• Objective evidence of impairment in one or more cognitive domains, typically including memory (i.e., formal or
bedside testing to establish level of cognitive function in multiple domains)
• Preservation of independence in functional abilities
• Not demented
Examine etiology of MCI consistent with AD pathophysiological process
• Rule out vascular, traumatic, medical causes of cognitive decline, where possible
• Provide evidence of longitudinal decline in cognition, when feasible
• Report history consistent with AD genetic factors, where relevant
MCI due to AD:
Intermediate likelihood
Clinical criteria + positive Aβ biomarkers and untested neuronal injury biomarkers
Clinical criteria + untested Aβ biomarkers and positive neuronal injury biomarkers
High likelihood
Clinical criteria+ positive Aβ and neuronal injury biomarkers
MCI- unlikely due to AD
Clinical criteria + negative Aβ and neuronal injury biomarkers
(Albert SA et al. 2011) [56]
Table 2. Mild Cognitive Impairment due to AD: National Institute on Aging (NIA) and the Alzheimer’s Association
diagnostic criteria 2011.
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Probable AD A. Insidious onset. Symptoms have a gradual onset over months to years, not sudden over hours or days
B. Clear-cut history of worsening of cognition by report or observation; and
C. The initial and most prominent cognitive deficit are evident on history and examination in one of the
following categories
a. Amnestic presentation is the most common syndromic presentation of AD dementia. The deficits should
include impairment in lerning and recall of recently learned information. There should also be evidence of
cognitve dysfunction in at least one other cognitive domain
b. Nonamnestic presentations:
• Language presentation: The most prominent deficits are in word-finding, but deficits in other cognitive
domains should be present
• Visuospatial presentation: The most prominent deficits are in spatial cognition, including object agnosia,
impaired face recognition, simultagnosia, and alexia. Deficits in other cognitive domains should be present
• Executive dysfunction: The most prominent deficits are impaired reasoning, judgment, and problem solving.
Deficits in other cognitive domains should be present
Possible AD Atypical course
A. Atypical course meets the core clinical criteria in terms of the cognitive deficits for AD dementia, but either
has a sudden onset of cognitive impairment or demonstrates insufficient historical detail or objective
cognitive documentation of progressive decline
or
Etiologically mixed presentation
B. Etiologically mixed presentation meets all core clinical criteria for AD dementia but has evidence as the
following:
a. Concomitant cerebrovascular disease, defined by a history of stroke temporally related to the onset or
worsening of cognitive impairment; or the presence of multiple or extensive infarcts or severe white matter
hyperintensity burden; or
b. Features of Dementia with Lewy bodies other than the dementia itself;
or
c. Evidence for another neurological diseases or a non-neurological medical comorbidity or medication use


















High but does not rule out second etiology
Aβ positive
Neuronal injury positive





1. Does not meet clinical criteria for AD dementia.
2. a. Regardless of meeting clinical criteria for probable or possible AD dementia, there is sufficient evidence
for an alternative diagnosis such as HIV dementia, dementia of Huntington’s disease, or others that rarely, if
ever, overlap with AD.
b. Regardless of meeting clinical criteria for possible AD dementia, both Aβ and neuronal injury biomarkers
are negative
(McKhann GM et al. 2011) [1].
Table 3. Dementia due to AD: National Institute on Aging (NIA) and the Alzheimer’s Association diagnostic criteria
The diagnostic procedure in clinical setting is usual divided into two phases. Screening is
used to formulate the diagnostic hypothesis and is followed by the diagnostic confirmation.
During the screening phase, the main point is to collect detailed information on history not
only from the patient itself, but also from the people who take care of patients such as fami‐
lial or other type of caregiver. Information about history includes medical history (presence
of severe medical disease that may cause encephalopathy, psychiatric disease, traumatic
brain injury or other neurological disease), medications, family history of dementia, and
changes in both basic activities of daily living (such as self-feeding, dressing and bathing,
ambulation) and instrumental activities of daily living (such as grooming, homework, man‐
age finances, driving, and leisure). To obtain information on activities daily living could be
particularly helpful to use standardized evaluation instruments such as Katz ADL scale [63]
Lawton-Brody IADL scale [64], and the Bristol Activities of Daily Living Scale [65]. In addi‐
tion to the history, a systematic assessment of general cognitive functioning is required
through instruments designed for this purpose. There are no screening tools that can quick‐
ly assess different levels of cognitive impairment. The American Academy of Neurology
guidelines suggested to use the Mini-Mental Status Examination [66], and the Memory Im‐
pairment Screen (MIS) [67]. In recent times, the Montreal Cognitive Assessment (MoCA)
was developed as a tool to screen patients in who has been hypothesized a mild cognitive
decline and usually performed in the normal range on the MMSE [68, 69]. Studies have
shown that MoCa is sensitive for the mild stages of AD dementia, whereas MMSE is superi‐
or for more advanced stages with the functional impairment. A complete summary of neu‐
ropsychological tests has been proposed [70].
After the screening, the second phase consists of a neurological examination, a neuropsycho‐
logical assessment, and a behavioural disease evaluation. A complete general neurological
examination has been recommended as well as accurate neuropsychological evaluation in
order to test possible differential diagnosis. The presence of Parkinsonism can suggest a
Lewy Body’s dementia, while asymmetric tendon reflex or other lateralizing signs can sug‐
gest a vascular component. Other neurological signs, for example peripheral neuropathy
may indicate toxic or metabolic problems. There is no evidence-based data to support the
usefulness of specific routine blood tests for evaluation of those with dementia but these are
useful in excluding co-morbidities. Most expert opinion advises to screen for vitamin B12,
folate, thyroid stimulating hormone, calcium, glucose, complete blood cell count, renal and
liver function abnormalities. Serological tests for syphilis, Borrelia and HIV should be con‐
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sidered in individuals at high risk [71]. Structural neuroimaging, computed tomography
(CT) or magnetic resonance imaging (MRI) is recommended as level B in the Dementia
Guideline [71] at least once in each patient in order to exclude other condition as neoplasms,
subdural hematomas. The lumbar puncture is not recommended unless the suspicion of
prion disease or viral encephalitis.
6. Biomarkers
A biomarker is any characteristic that is objectively measured and evaluated as an indicator
of biologic or pathogenic process and it should also be reliable, non-invasive and simple to
perform [72]. Regarding AD, biomarkers included in the new diagnostic criteria are a meas‐
urement of the underline pathology and can be divided in markers of amyloid accumulation
(CSF Aβ level, PET with amyloid-tracers) and markers of neuronal injury (atrophy of MTL
at MRI, tau level in CSF, metabolic PET) [55]. Table 4 shows all the biomarkers.
6.1. Medial temporal lobe atrophy
Bilateral atrophy of medial temporal lobe structures, including hippocampus, has been
found in patients with AD (Figure 1). Moreover it has been reported that the brain atrophy
detected with neuroimaging reflects the typical pattern of progression of neuropathology,
spreading from entorhinal cortex and hippocampus to the association cortices, as describe
by Braak and Braak [73, 74]. In a meta-analysis of studies using visual and linear measure‐
ments of medial temporal lobe atrophy (MTA) on MRI, the overall sensitivity and specificity
for detection of AD compared with controls was estimated to be 85% and 88%, respectively
[75]. A yearly decline in hippocampal volume is approximately 2.5 times greater in patients
with AD than in normal aged subjects. In clinical practice simple visual rating scales esti‐
mating hippocampal atrophy has proven to be useful to support the diagnosis in the first
stage of the disease [74]. Although MTL is a biomarker of neurodegeneration and a good
surrogate of disease progression, it has low sensitivity and specificity (51-70% and 68-69%,
respectively) in identifying prodromal AD stage [76].
Figure 1. Coronal T1-weighted MRI scans of control (left) and patient with AD (right). The patient with AD shows atro‐
phy of the hippocampus (arrow) [74].




PET with traced glucose (FDG-PET) shows brain metabolism and reflects pattern of neuro‐
degeneration. Metabolic reduction in bilateral temporal- parietal regions and in posterior
cingulate is the most commonly described diagnostic criterion for AD [77].This specific pat‐
tern significantly predicts decline to AD with an average overall accuracy of 86%, and with
sensitivity and specificity about 75-80%. Moreover some studies on pre-symptomatic carri‐
ers of genetic mutations for AD revealed FDG-PET hypometabolism many years before the
clinical onset of the disease [78,79].
6.3. PET with amyloid-tracers
Interestingly recently has been developed a technique to detect amyloid in vivo using PET.
[18F]-FDDNP and [11C] Pittsburgh compound-B (PIB) were the first amyloid PET tracers
developed. Both tracers bind with nanomolar affinity to amyloid and enter the brain in
amounts sufficient for imaging with PET. Retention of the tracers in neocortical and subcort‐
ical brain regions was significantly higher in AD patients than in controls. In subjects with
MCI and positive retention the rate of progression to AD is estimated 25% per year [80]. A
recent meta-analysis estimated a sensitivity of 93% and specificity of 56.2% [78]. Similarly,
genetic at-risk cohorts demonstrate evidence of Aβ accumulation many years before detecta‐
ble cognitive impairment [79]. This method could be used to follow the therapeutic efficacy
of the new AD immunotherapies.
6.4. CSF Aβ and tau
Many reports have demonstrated a decline in CSF Aβ and elevation of total tau, phospho-
tau, and tau/Aβ ratio in AD subjects. The reduction of Aβ could be by about 50% in subjects
with AD compared with age-matched controls [81] and this phenomenon is thought to re‐
sult from deposition of Aβ into plaques, leaving less Aβ being available to diffuse into the
CSF. CSF total tau reflects the intensity of the neuronal and axonal damage, and it is in‐
creased in AD subjects by 2-3 folds compare with controls. However, tau, as a marker of
neuronal injury, can be transiently increased after any acute brain injury (such as stroke or
trauma) [82]. A comprehensive review [83] reports that Aβ shows a sensitivity and specifici‐
ty of 86% and 90%, respectively, in differentiating AD from controls. For tau, the sensitivity
is 81% and the specificity 90%, and p-tau has a mean sensitivity of 80% when specificity is
set at 92%. By use of a combination of concentrations of Aβ42 and t-tau for AD versus con‐
trols, high sensitivities (85–94%) and specificities (83–100%) can be reached. The reliability of
CSF biomarker has been tested by the comparison with autopsy results, showing high sensi‐
tivity and specificity in discriminating AD from both the cognitively normal elderly and
from patients with other dementias. These CSF markers have also been shown to predict AD
in patients with MCI [84], and to precede symptoms in familial AD [85]. However CSF bio‐
markers are not related with dementia severity.
Biomarkers, despite their great potential especially in the research field, are not recommend‐
ed for the routine use in clinical diagnostic setting. Clinical criteria provide very good accu‐
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racy, there is limited standardization of the biomarkers and the access is limited to
university hospitals.
Specificity Sensitivity
Biomarkers of Aβ deposition
CSF Aβ [83] 90% 86%
PET amyloid imaging [78] 56.2% 93.5%
Biomarkers of neuronal injury
CSF tau [83] 90% 81%
Medial temporal lobe atrophy on MRI [75] 88% 85%
FDG-PET imaging [78] 74% 78.7%
Table 4. Alzheimer´s disease biomarkers: diagnostic accuracy
7. Others biomarkers
7.1. CSF BACE1 and sAPP
APP, amyloid precursor protein, is sequentially cleaved by α-or β-secretase (BACE1), fol‐
lowed by γ-secretase enzyme. The cleavage by BACE1 and γ-secretase generates Aβ pep‐
tide,  likely  to  aggregate  in  plaques,  and  the  N-terminal  secreted  fragment  of  APPβ
(sAPPβ).  In  contrast,  APP  cleavage  by  α-and  γ-secretase  generates  non-amyloidogenic
fragments and secreted fragment of APPα (sAPPα). Thus, CSF BACE1 activity and sAPPβ
and sAPPα proteins  have  been  testing  to  provide  information  about  amyloidogenic  vs.
nonamyloidogenic processing in the brain. Although some reports have shown higher lev‐
els  of  CSF  BACE1 activity  in  AD compared with  healthy  controls  and higher  levels  in
subjects with MCI who progress to AD, others have not observed these, or have shown a
decline of BACE1 activity in AD [86]. It is possible that CSF BACE activity is elevated in
incipient  AD  and  subsequently  decline  with  disease  progression.  Several  groups  have
measured  CSF  sAPPβ  and  sAPPα  levels  from  AD  and  control  subjects  to  understand
brain APP metabolism better. Some studies reported higher levels of sAPPβ and a reduc‐
tion in sAPPα levels in AD, however, these results need further confirmation [86].
7.2. Plasma Aβ
Several studies investigated plasma level of Aβ in AD. One group of researchers reported
that in patients with newly acquired Alzheimer’s disease, the plasma Aβ levels decline sig‐
nificantly compared with controls or participants with prevalent Alzheimer’s disease during
an average follow-up period of 3 years [87]. Another study reported that higher baseline
plasma Aβ concentrations and greater reductions in plasma Aβ concentrations were associ‐
ated with cognitive decline in non-demented elderly people over 4 years follow-up [88].
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This study indicated that plasma Aβ level is elevated during the pre-symptomatic stage in
at-risk individuals, but subsequently start falling with the development of Alzheimer’s dis‐
ease/MCI. Anyhow most groups have not found any significant differences between pa‐
tients and controls. Wu and colleagues [86] recently tried to measure, through specific
antibody, plasma level of BACE1, sAPPβ and sAPPα. They reported significant increase in
plasma BACE activity, sAPPβ, and sAPPα in a small sample of AD patients (n=20) com‐
pared with age-matched controls (n=30).
7.3. Clinical variants of Alzheimer´s disease
The  common conception  of  Alzheimer’s  disease  (AD)  is  a  disorder  that  initially  affects
memory  function,  associated  with  early  pathological  changes  in  medial  temporal  lobes,
and progresses  to  involve  language,  visuospatial  skills  and other  cognitive  abilities,  re‐
flecting progressive involvement of association neocortices [61]. It is recognised, however,
that  the  clinical  presentation of  AD is  variable  and in  some cases  the  presenting domi‐
nant symptom is not memory [89-91]. Non-amnestic presentations are frequently referred
to as “focal” presentations of AD. It is well established that most patients with a progres‐
sive disturbance of  aspects  of  visuo-perceptual  and spatial  abilities,  often referred to  as
posterior cortical atrophy, have underlying AD pathology. In addition, it is now clear that
a  proportion of  patients  with  progressive  aphasia,  both  fluent  and non-fluent  type,  can
have AD as the primary pathology. Recently, cases of corticobasal syndrome (CBS) secon‐
dary to AD pathology have also been reported [90].  The existence of a frontal presenta‐
tion is more controversial. Patients with familial AD secondary to presenilin 1 mutations
may have a behavioural onset [92, 93] and there are isolated reports of sporadic AD re‐
sembling fronto-temporal dementia (FTD) [91, 94].
7.4. Progressive aphasia
Primary progressive  aphasia  (PPA)  is  a  clinical  syndrome in  which cognitive  decline  is
limited to one or more components of the language system. Since Mesulam’s first descrip‐
tion of the phenomenon [95] clinical,  neuropsychological and imaging studies have con‐
verged  on  the  existence  of  three  distinct  clinical  subtypes:  semantic  dementia  (SD),
characterized by fluent but empty speech, impaired comprehension and high incidence of
dyslexic errors, in association with selective atrophy in anterior temporal regions; non flu‐
ent/agrammatic  aphasia  (PNFA)  with  phonologically  and/or  grammatically  distorted
speech output, preserved single word comprehension, and atrophy focused on the left in‐
ferior frontal and insular regions; logopenic variant ( LPA), characterized by a slow pro‐
duction  rate,  long  word  finding  pauses,  sparse  phonological  paraphasias  and  difficulty
with sentence (but not single word) repetition. MRI reveals abnormalities in more posteri‐
or brain regions [96]. Pathologically, PNFA and SD are more likely to present an FTD pat‐
tern,  although  in  some  cases  they  can  be  the  clinical  presentation  of  atypical  AD
pathology.  In contrast,  biochemical,  amyloid imaging and post  mortem findings in LPA
support  the  idea  that  the  syndrome is  a  clinical  marker  of  AD pathology [97].  Clinical
evolution of that variant leads to mutism and memory impairment.
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7.5. Visual variant
Posterior cortical atrophy (PCA) or visual variant of AD is characterized by early impair‐
ment of visuo-spatial skills with less prominent memory loss and is associated with atro‐
phy  in  parieto-occipital  and  posterior  temporal  cortices  with  right  predominance  [98].
Clinical presentation includes difficulties in reading lines of text, in judging distances, in
identifying static objects within the visual field, alexia, and features of Balint's syndrome
(simultanagnosia,  oculomotor  apraxia,  optic  ataxia,  environmental  agnosia)  and  Gerst‐
mann's syndrome (acalculia, agraphia, finger agnosia, left–right disorientation) [99]. Defi‐
cits in working memory and limb apraxia have also been noted [100].  By the time PCA
has run its course, many patients develop also memory and language deficits. Findings of
pathological  studies  all  show that  Alzheimer's  disease  is  the  most  common underlying
cause of PCA [101]. Some studies have shown that PCA cases have the greatest density of
both plaques and neurofibrillary tangles in visual and visual-association cortices and few‐
er tangles and senile plaques in the hippocampus and subiculum [101].  CSF biomarkers
(Aβ,  tau, and P-tau) show similar pattern in patients with PCA compared with AD sub‐
jects,  supporting  the  hypothesis  that  PCA  is  associated  typically  with  underlying  Alz‐
heimer's disease pathology. However, some cases are attributable to other causes, such as
corticobasal degeneration, dementia with Lewy bodies, or prion disease [98].
7.6. Progressive apraxic syndrome
Autopsy proven AD cases can be related to an apraxis clinical syndrome. Patients with these
phenotype present progressive loss of use of the limbs which compromises performance on
manual tasks such as dressing, handling a knife or a fork and writing. Cognitive assessment
reveals apraxia and in less extends deficits in spatial function, with initially preserved mem‐
ory [102]. The clinical spectrum of that phenotype may also include others symptoms of the
corticobasal syndrome (CBS), as asymmetric parkinsonism, ideomotor apraxia and alien
limb phenomena. CBS is an unusual clinical manifestation of various neurodegenerative
pathologies, AD, FTD, corticobasal degeneration (CBD). The one related to AD presents a
temporo-parietal atrophy prevalent on the left side and hypoperfusion of parietal lobe, with
less involvement of pre-frontal regions compare with FTD and CBD [103].
7.7. Frontal variant
Sometimes AD patients presents a prevalent impairment of the executive function in the
early stages of the disease, but there is also a multidomain deficit [90, 102]. Two reports,
[91,  94]  have  claimed that  a  behavioural  onset  of  cognitive  dysfunction,  with  disinhibi‐
tion, apathy and personality change could be also an atypical presentation of AD patholo‐
gy.  Alladi  and colleagues  [90]  after  the  examination  of  28  cases  of  behavioral  variant  -
FTD  found  AD  pathology  in  two  cases.  None  of  the  two  patients  had  amnesia  at  the
onset  of  the disease,  but  in  both cases  diffuse cognitive dysfunction developed early  in
the course of the disease. Authors concluded that a behavioural variant of AD exists, but
in contrast to patients with non-AD pathology, the disease does not appear to remain re‐
stricted to the frontal lobes for very long.
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8. Treatment and management
Regarding the therapeutic management of a disease generally there are at least three possi‐
bilities: (i) prevention strategy, (ii) symptomatic treatment, and (iii) disease modifying thera‐
pies. Currently, a long list of factors that can reduce or delay the risk of AD onset has been
reported, but so far there is no certain evidence supporting the prevention efficacy in AD. In
Europe, there are three ongoing multidomain interventional random clinical trials (RTCs)
that focus on the optimal management of vascular risk factors and vascular diseases and in‐
clude also medical and lifestyle interventions. The results of the RTCs might help in improv‐
ing strategies of dementia prevention [3]. This indicates the principle type of AD treatment
is based on symptomatic drugs. There is no cure for AD, but new types of disease modifying
treatments are under investigation. Non-pharmacological interventions have been also re‐
cently added in AD patient management.
8.1. Symptomatic treatments: acetylcholinesterase inhibitors
The neuropathology of Alzheimer’s disease is characterized by early loss of basal forebrain
cholinergic neurons, leading to decreased cholinergic transmission which is involved in
many aspects of cognition, including memory and attention. Inhibitors of the acetylcholines‐
terase enzyme (AChEIs) increase acetylcoline level in brain, which leads to memory im‐
provement. Since the introduction of the first ChEI in 1997, these agents are considered first-
line pharmacotherapy for mild to moderate AD stages [71]. Four ChEIs are currently
available: tacrine, donepezil, rivastigmine and galantamine. Tacrine (Cognex), the first ap‐
proved, is not commonly used because of a poor tolerability profile and low oral bioavaila‐
bility [104]. The Cochrane’s Review [105] of placebo controlled trials of ChEIs demonstrated
that the treatment determine an improvement of 1.4- to 3.9-point in the ADAS-Cog scale at 6
months and 1 year. In clinical trials, a change of 4 points is considered clinically significant
for patients with mild to moderate dementia. In addition to their effects on cognition, these
agents also have demonstrated beneficial effects on measures of behavior, activities of daily
living (ADLs), and global patient function as reported in a recent meta-analysis [106]. Done‐
pezil (Aricept) was approved in the mid-1990s. The starting dose is 5 mg once daily which
can be increased after 4 weeks to 10 mg, if well tolerated. The common side effects are nau‐
sea, vomiting, gastritis and diarrhea. The length of the response has been documented up to
52 weeks. When donepezil is discontinued, performance of the subject returns to the same as
in the untreated state. Rivastigmine (Exelon) is a pseudo-irreversible inhibitor as it dissoci‐
ates from the enzyme slowly. Two type of administration are available: oral and transder‐
mal patch. The oral starting dose is 1,5 mg twice daily that can be weekly increase of 1,5 mg
until a total amount of 12 mg per day (6 mg twice daily). The transdermal patch last 24
hours and has two dosages: 4,6 mg and 9,5 mg. The target dose, 9,5 mg/24 h, can be reached
after 4 weeks if the low dosage is well tolerated. Side effects of oral Rivastigmine are ap‐
proximately the same as donepezil, while gastrointestinal symptoms are at least three times
less prominent with the patch [104]. Rivastigmine is also an inhibitor of butyrylcholinester‐
ase that facilitate cholinergic neurotransmission by slowing the degradation of acetylcholine
released by functionally intact cholinergic neurons. The therapy with Galantamine (Remin‐
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yl) starts with 4 mg twice daily and increases in increments of 4 mg per dose twice a day to a
maximum of 12 mg twice daily if tolerated. Currently it is also available in an extended-re‐
lease formulation that can be taken once daily. Galantamine has some nicotinic receptor ac‐
tivity. All AChEIs can influence cardiac rhytm, but is not common unless a person has an
underlying disturbance in cardiac conduction. An electrocardiogram prior to initiating the
treatment is recommended. AChEIs may also have an effect on respiratory conditions, such
as chronic obstructive pulmonary disease or asthma, or gastrointestinal disease, such as gas‐
tric ulcer. The absorption of AChEI is not influenced by food intake. These agents are recom‐
mended for the treatment for patient only in the mild and moderate stages [71].
8.2. Memantine
Memantine is an NMDA (N-methyl-D-aspartate) receptor antagonist that reduces glutama‐
tergic excitotoxicity. Based on the glutammatergic hypothesis of AD, Memantine has been
claimed to be a disease modifying therapy. Clinical trial with Memantine reports a mild effi‐
cacy in maintaning functional level in patients with severe dementia [107]. Memantine is li‐
censed for the treatment of people with moderate-to-severe AD. The starting dose is 5 mg
that can be increased of 5 mg every week up to the dose of 20 mg. Side effects are very un‐
usual and include restlessness, hyperexitation and fatigue. There are good evidence of clini‐
cal benefit in patients moving into severe stages of AD from a combination therapy with
Memantine and an acetylcholinesterase inhibitor [108-110].
8.3. Disease-modifying treatments
Since the role of beta amyloid (Aβ) is considered to be paramount in the development of
AD, several research strategies have been undertaken to alter the biochemistry of Aβ in the
brain through interference of either the formation or the deposition of Aβ. The amyloid pre‐
cursor protein can be processed in two different pathways, non-amyloidogenic by α-secre‐
tase and amyloidogenic ones by β-secretase followed by γ-secretase [12]. Thus, the
inhibition of β or γ-secretase is the target of therapies that aim to reduce the production of
Aβ, while new immunotherapeutic strategies promote removal of Aβ from the brain. Drugs
that can act as β-secretase inhibitors belong to a group of type 2 diabetes therapies, thiazoli‐
dinediones (rosiglitazone and pioglitazone). Despite the promising biological plausibility of
these compounds, the results of randomized clinical trials (RCTs) have been disappointing
[111-112]. A number of γ-secretase modulators (semagacestat and tarenflurbil) have also
failed to provide benefits in the treatment of AD [113,114]. Immunotherapies or “vaccines”
are based on both active and passive immunization. Initial approaches based on immuniza‐
tion with Aβ fragments performed extremely well in transgenic mouse models but showed
less promise in humans [51]. The most promising of these, AN-1792 (QS-21) resulted in sig‐
nificant Aβ-antibody titers in patients with mild-to-moderate AD in Phase II trials. Postmor‐
tem analysis on long-term follow-up also confirmed that the therapy had resulted in a
significant reduction in Aβ burden in the brain. However, there was no evidence of any clin‐
ical benefit and the trial was halted owing to patients developing aseptic meningoencephali‐
tis, thought to have been induced by cytotoxic T-cell activation. Immunotherapies have
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since been designed using shorter peptides designed to mimic immunoreactive sections of
Aβ, in an effort to avoid severe inflammatory response. There are various immunotherapies
taking these approaches. For example, CAD-106, which targets Aβ1–6, resulted in Aβ clear‐
ance without collateral immunoreactivity in Phase I trials, and is now in a Phase II RCT. Pas‐
sive immunotherapy for AD has met with some criticism owing to the challenge of
designing an approach that can achieve significant antibody concentrations in the brain. Al‐
though some of the data from animal studies do suggest a possible impact on oligomer for‐
mation and brain amyloid load. Currently, monoclonal antibody therapies include
bapineuzumab (AAB-001) and solanezumab (LY-2062430) that are now in a phase III RCT
[115]. The results of these trials are eagerly awaited, but experts’ consensus is not anticipat‐
ing positive outcomes. Despite the facts that vaccines can remove Aβ from the brain, a fun‐
damental debate continues around the clinical benefit of Aβ clearance. Neurofibrillary
tangles are another hallmark of AD pathology, however treatments to target tauopathy have
received far less attention than amyloid therapies. Very preliminary results in animal mod‐
els have shown that a tau immunotherapy might be a valuable approach [116].
8.4. Non-pharmacological treatment
In the last ten years there has been a great public interest in possible non-pharmacological
therapies to delay disease progression and functional decline. The psychosocial interven‐
tions fitted to this goal and they were developed based on the concept of “cognitive re‐
serve”. Evidence from meta-analyses and systematic reviews has shown that a higher
cognitive reserve is associated with a significantly reduced risk to develop dementia [117].
Generally “cognitive reserve” describes the mind’s resistance to damage of the brain. There
has been proposed two models to explore the reserve, a passive model called “brain re‐
serve” and an active model knows as “cognitive reserve” [118]. There are several different
approaches to neuropsychological and training interventions focusing on cognition with dif‐
ferent evidence for efficacy in people with AD. In large part, the psychosocial interventions
have shown significant, but modest effect-size when used alone. The American Association
for Gertiatric Psychiatry (AAGP) proposed a care/treatment model that combines pharmaco‐
logical therapies with psychosocial intervention for people with AD [119]. To date, the liter‐
ature about psychosocial intervention is wide [120-123]. For this reason we decide to
illustrate briefly the most important intervention below. The psychosocial interventions can
be classified according to the treatment goal and include behaviour, emotion-oriented and
stimulation-oriented treatment, and cognitive training [124].
Behaviour-oriented therapy is used to modify dysfunctional behaviour employing behav‐
iour change techniques which increase or decrease the frequency of behaviour through the
use of reinforcement, punishment, and extinction following the Experimental Analysis of
Behaviour (B.F. Skinner). Behaviour therapy is helpful to reduce typical behaviour’s prob‐
lems such as incontinence and wondering [125-127]. Stimulation-oriented interventions in‐
clude recreational activities such as creative arts (such as craft, music, dance, andtheatre)
and leisure education, art therapy, music therapy, pet therapy, and other formal activities
aim to maximize pleasurable activities for the patients. Stimulation improves modestly be‐
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haviours and mood, but the main effect is to change the daily-life routine [124]. Emotion-
oriented approaches include supportive psychotherapy, reminiscence therapy, validation
therapy, sensory integration (snoezelen), and simulated presence therapy (SPT). Supportive
psychotherapy has not received formal scientific studies, but can be used to address issue of
loss in the early stage of AD and help mildly impaired patients to adapt themselves to a new
lifestyle imposed by the disease. Reminiscence therapy remains controversial, individually
or in group, on past life events of the patient helped by using external aids such as photo‐
graphs, household items, music and sound recordings, or other familiar items from the past.
The final goal is to improve the psychological well-being, mood, and coping skills of pa‐
tients with AD [128]. Researches have shown that reminiscence is useful to improve directly
emotions in overall mood, thus can improve cognitive functioning [129-132]. Validation
therapy [133] is based on the empathic relationship between the patient and the therapist.
Drug Suggested Dosage Approved indication
Cholinesterase inhibitors
Donepezil (Aricept) 5 mg once daily, which can be increased to
10 mg/day after 4 weeks
Mild to moderate AD
Sever AD in add-on with
Memantine
Rivastigmine (Exelon) Oral: Twice daily starting with 1.5 mg which
can be increased up to 6 mg twice daily in 6
weeks
Transdermal patch: once daily, 4,6 mg/24 h,
or 9,5 mg/24 h.
Mild to moderae AD
Galantamine (Remynil) Twice daily, beginning with 4 mg and
increase after 4 weeks to 8 mg twice daily. A
dosage of 12 mg twice daily can also be
reached after a medical examination
Availabe a new extended-release
formulation that can be taken once daily
Mild to moderate AD
NMDA atagonist
Mematine (Ebixa) Twice daily beginning with 5 mg increase
up to 10 mg twice daily in 4 weeks
Available a dosage of 20 mg that can be
taken once daily










*RCT= randomize clinical trial
Table 5. Alzheimer’s disease pharmacological treatments
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Through listening, the therapist examines the reality’s perception of the patient in order to
create significant emotional and relational contacts. The objectives are to stimulate the pa‐
tient to take social role, stimulate verbal communication, and encourage social interaction.
Validation is intended for patients with severe to moderate dementia. Cognitive training in‐
volves guided practice on a set of standard tasks designed to stimulate specific cognitive
functions (memory, attention, or problem-solving). The underlying assumption is that prac‐
tice may improve or maintain functioning in a given domain, generalizing the effects of
practice beyond the clinical context to everyday life [121].The aim is to reduce cognitive defi‐
cits. The Reality Orientation Therapy (ROT) is a technique widely used in treatment of AD
[134-136]. The objective is to stimulate the personal, time, and space orientation in the pa‐
tient through repeated multimodal stimulation (verbal, visual, and musical), strengthen the
basic information with respect to space and time coordinates, and his personal history. The
level of stimulation is modulated agree with residual cognitive resource of patient. Other
types of cognitive training include skills training and cognitive retraining focusing on cogni‐
tive deficits. There has been demonstrated that cognitive training improve cognitive func‐
tioning, but effects were transient and often accompanied by negative effects linked to
frustration [137]. Finally, the caregivers are also part of the treatment and should be careful‐
ly managed overtime.
9. Conclusions
Alzheimer´s disease is a common disorder of aging, and a major cause of dependence and
mortality among elderly. Substantial progress has been made over the past few decades in
understanding AD. Nevertheless, our knowledge of this disease is still profoundly imper‐
fect, as demonstrated by the failure of all but symptomatic treatments for clinically diag‐
nosed AD. We know that in people aged >85 years, dementia and cognitive impairment are
common, reaching a combined prevalence >50% in the oldest old, and that the incidence of
dementia continues to rise in the oldest age groups. Thus, screening is essential to identify
cognitively normal individuals in midlife or old age who have a high risk of developing
MCI and AD, so that interventions, when available, can be administered to stop the devel‐
opment of specific disease-related pathologies. Although the exact pathogenetic mechanism
of AD is still unclear, thanks to new technologies, we are now able to detect in vivo subjects
with AD-related brain pathological changes. Many studies have provided evidence that AD
pathology begins as many as 20 years before symptoms appear. These findings determined
a new concept of AD, where the symptom of dementia represents the final part of the “con‐
tinuum” of AD. Recently, based on the new knowledge about AD, some disease modifying
therapies have been developed and their results are eagerly awaited.
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